This content is in French.
Remdesivir: a real turning point against COVID-19?
12 mai 2026
By Ana Espino | Published on May 12, 2026 | 4 min readCOVID-19 is a respiratory infection caused by SARS-CoV-2, responsible for a global pandemic that led to millions of hospitalizations and deaths. Severe forms of the disease can cause significant pneumonia, acute respiratory failure, and may require oxygen therapy or mechanical ventilation. At the beginning of the pandemic, very few effective tr
By Ana Espino | Published on
May 12, 2026 | 4 min read
COVID-19 is a respiratory infection caused by SARS-CoV-2, responsible for a global pandemic that led to millions of hospitalizations and deaths. Severe forms of the disease can cause significant pneumonia, acute respiratory failure, and may require oxygen therapy or mechanical ventilation.
At the beginning of the pandemic, very few effective treatments were available against SARS-CoV-2, and patient management relied mainly on supportive care. Remdesivir, an antiviral initially developed against Ebola, was quickly identified as a potential candidate because of its action on viral replication. However, its actual effectiveness in hospitalized patients remained uncertain.
COVID-19 is a respiratory infection caused by SARS-CoV-2, responsible for a global pandemic that led to millions of hospitalizations and deaths. Severe forms of the disease can cause significant pneumonia, acute respiratory failure, and may require oxygen therapy or mechanical ventilation.
At the beginning of the pandemic, very few effective treatments were available against SARS-CoV-2, and patient management relied mainly on supportive care. Remdesivir, an antiviral initially developed against Ebola, was quickly identified as a potential candidate because of its action on viral replication. However, its actual effectiveness in hospitalized patients remained uncertain.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Rouhana El Feghali Y, et al. Remdesivir in COVID-19: pros and cons. Front Pharmacol. 2026 Feb 12;17:1731244. doi: 10.3389/fphar.2026.1731244. PMID: 41769697; PMCID: PMC12936022.
View on PubMed
